Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 28Carcinoma, Hepatocellular 25Colorectal Neoplasms 23Carcinoma, Non-Small-Cell Lung 13Melanoma 12Stomach Neoplasms 10Colonic Neoplasms 10Liver Neoplasms 9Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 7Carcinoma, Transitional Cell 7Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Ovarian Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Prostatic Neoplasms 5Lung Neoplasms 5Gastrointestinal Stromal Tumors 5Esophageal Neoplasms 5Carcinoma 5Urinary Bladder Neoplasms 4Turcot syndrome 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma 4Mesothelioma 4Endometrial Neoplasms 4Cholangiocarcinoma 4Carcinoma, Merkel Cell 4

Interventions

3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 4pimonidazole 2TH 302 2pembrolizumab 1inositol trispyrophosphate 1gadobutrol 1fluoromisonidazole 1Tirapazamine 1Surgical Procedures, Operative 1Radiotherapy 1Propofol 1Pancreaticoduodenectomy 1Paclitaxel 1Ipilimumab 1Injections 1Gemcitabine 1Ethiodized Oil 1Cisplatin 1Blood Specimen Collection 1Biopsy 1AQ4N 14-methylbenzenesulfonic acid 13-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypoxia × Ipilimumab × Gastrointestinal × Clear all
NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Threshold Pharmaceuticals

Phase 1 Unknown
69 enrolled
DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡